Xenetic Biosciences, Inc. · NASDAQ:XBIO
Xenetic Biosciences — Merger or Acquisition (September 2026)
26 slides from Xenetic Biosciences's merger presentation, September 2026
Slide 1: Advancing NET-Targeted Therapies for Immune-Driven Diseases and Cancer
Advancing NET-Targeted Therapies for Immune-Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026
Slide 2: Disclaimer
Disclaimer This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed t
Slide 3: Transaction Valuation and Pro Forma Capitalization
Transaction Valuation and Pro Forma Capitalization Shares Outstanding / Ownership in Pro- Transaction Issued Forma Company Valuation(4) Shares outstanding Xenetic Biosciences (fully diluted, restricted stock 2,546,699(1) ~15.0% $21 million(3) and shares underlying options) New Xenetic shares issued
Slide 4: Transaction Highlights
Transaction Highlights Proposed Transaction is Expected to Close in the Fourth Quarter of 20261 Definitive Share Combined Company Ownership Exchange Agreement Santersus will become a wholly owned At closing, each outstanding Santersus share Pre-transaction Santersus shareholders are subsidiary of Xe
Slide 5: Pioneering Breakthrough NET-Targeted Therapies to Transform the Treatment Paradigm
Pioneering Breakthrough NET-Targeted Therapies to Transform the Treatment Paradigm of Immune-Driven Diseases and Cancer Positive clinical outcomes with no adverse events NET-Targeting Platforms across 80+ compassionate use cases in patients with sepsis, autoimmune disease and cancer NucleoCapture® t
Slide 6: Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics Advancing a Pipeline of Multiple Billion-Dollar Opportunities NucleoCapture® DNase Blood Purification Device for Pharmacological / Enzymatic for Circulating NETs Tissue Based NETs Removes NETs directly from cir
Slide 7: Excessive and Persistent NETs Are Convergent Upstream Driver of Inflammation
Excessive and Persistent NETs Are Convergent Upstream Driver of Inflammation, Tissue Injury, Immune Dysregulation and Treatment Resistance Neutrophil extracellular traps (NETs) are web-like structures composed of DNA, histones and antimicrobial proteins released by activated neutrophils to trap and
Slide 8: Advancing Two NET-Targeted Platforms Across Immune-Driven Diseases and Cancer
Advancing Two NET-Targeted Platforms Across Immune-Driven Diseases and Cancer THERAPEUTIC BLOOD PURIFICATION DEVICE PIPELINE PROGRAM INDICATIONS INITIAL CLINICAL STAGE PIVOTAL CLINICAL TRIAL APPROVAL KEY HIGHLIGHTS • Recruitment in progress Sepsis • Interim analysis and CE Mark in Combination with S
Slide 9: NucleoCapture: FDA-Designated Breakthrough Treatment for Sepsis
NucleoCapture®: FDA-Designated Breakthrough Treatment for Sepsis Proprietary therapeutic blood purification device that physically bind to and remove NETs from blood circulation without affecting neutrophils defensive functions Ongoing pivotal multicenter study, up to 350 patients with sepsis and re
Slide 10: Demonstrated 100% 7-Day Survival with Rapid Reductions in Circulating NET Levels
Demonstrated 100% 7-Day Survival with Rapid, Repeated Reductions in Circulating NET Levels in Sepsis Patients Reduction in Circulating Net Levels Reduction in Key Biomarkers Circulating NET Level, ng/mL Treatment n=10 Treatment Treatment Before After Before After Before After Before After Circulatin
Slide 11: Ongoing Pivotal Multicenter Study for Treatment of Sepsis and Respiratory Failure
Ongoing Pivotal Multicenter Study for Treatment of Sepsis and Respiratory Failure Study Design Number of Subjects: up to 350 Treatment: SoC or SoC + NucleoCapture® Primary Effectiveness Endpoint: Randomized: 1:1 Composite outcome evaluated using win ratio methodology: • All-cause mortality through D
Slide 12: NucleoCapture: FDA-Designated Breakthrough Treatment for SLE
NucleoCapture®: FDA-Designated Breakthrough Treatment for SLE In a retrospective analysis of compassionate use cases (n=10), three treatments were associated with immediate powerful reduction of disease activity, clinical manifestations and broad quality-of-life improvements 54% Reduction in Disease
Slide 13: NucleoCapture: Restoring Viability in Donor Organs During Ex Vivo Machine Perfusion
NucleoCapture®: Restoring Viability in Donor Organs During Ex Vivo Machine Perfusion Liver Revitalization Targeting a 15-month FDA regulatory pathway through a supplement to the existing OrganOx metra® PMA Improved viability-associated parameters in 8 discarded human liver grafts meeting ex vivo tra
Slide 14: DNase for LBCL: Overcoming Tumor Immune Evasion
DNase for LBCL: Overcoming Tumor Immune Evasion Removal of barrier to CAR T cells EGFR CAR T EGFR CAR T plus DNase Deoxyribonuclease I (DNase) is a human endonuclease enzyme responsible for degrading NETs in tissues and blood via enzymatic cleavage of NETs DNA backbone • Investigator-initiated study
Slide 15: Leadership and Development Team
Leadership and Development Team Andrew Aswani, MD Dmitry Genkin, MD Elisabeth Barabash, James Ladtkow BS, MS BSME, MBA PhD MRCP FRCA Chief Scientific Officer Chief Clinical Operations Chief Executive Officer EDIC FFICM Chief Medical Officer and SAB Chairman 35+ years in medical device development. C
Slide 16: Upcoming Value Driving Milestones
Upcoming Value Driving Milestones NucleoCapture® NucleoCapture® NucleoCapture® DNase Liver Transplantation Large B-Cell Sepsis SLE Program Program Lymphoma Program Q4 2027 Q1 2027 Q1 2027 Q2 2027 First Interim Analysis First Patient In Exclusive License and Supply Enrollment Completed (100 patients)
Slide 17: Positioned to Lead the Emerging Field of NET-Targeted Therapeutics
Positioned to Lead the Emerging Field of NET-Targeted Therapeutics Clear Path Building an integrated therapeutic Diversified Toward Potential portfolio around NETs, an increasingly Pipeline Commercialization recognized driver of disease progression across immune-driven Four prioritized programs Lead
Slide 18: Advancing NET-Targeted Therapies for Immune-Driven Diseases and Cancer
Advancing NET-Targeted Therapies for Immune-Driven Diseases and Cancer Thank you!
Slide 19: Appendix
| Appendix
Slide 20: NucleoCapture: Breakthrough Treatment for SLE
NucleoCapture®: Breakthrough Treatment for SLE NucleoCapture® is designed to selectively remove circulating NETs, potentially reducing the autoantigen and inflammatory burden without suppressing immune cells. Excessive NET formation and impaired clearance expose autoantigens, amplify type I interfer
Slide 21: SLE: Significant Reduction in SLE Disease Activity in Retrospective Analysis
SLE: Significant Reduction in SLE Disease Activity in Retrospective Analysis After 3 Indicator Before NucleoCapture® 54% Reduction in Disease Activity Treatments • Median SLEDAI-2K decreased from 17.5 to 8.0 after three treatments p=0.009 SLEDAI, Me 17.5 [10; 25] 8.0 [4; 12] [25th; 75th percentiles]
Slide 22: SLE: Quality-of-Life Improvements in Patients with SLE Flares
SLE: Quality-of-Life Improvements in Patients with SLE Flares After The Course Improvement in Key Indicator Before of Procedures Lupus QoL In a retrospective analysis, Physical Health (↑ = Improvement) 57.8 [42.2; 67.2] 76.6 [51.6; 92.2] patients (n=10) reported broad Pain 58.3 [41.7; 70.8] 87.5 [66
Slide 23: Upcoming Pivotal Multicenter Study in EU and Hong Kong for Treatment of SLE
Upcoming Pivotal Multicenter Study in EU and Hong Kong for Treatment of SLE Anticipated Development Path to Potential Commercialization in US and EU Study Design Number of Subjects: up to 110 with Randomized: 1:1 active SLE, SLEDAI-2K score ≥ 8 Primary Effectiveness Endpoint: Treatment: SoC or SoC +
Slide 24: Demonstrated Sustained cfDNA Reduction and Metabolic Recovery in Discarded Human Livers
Demonstrated Sustained cfDNA Reduction and Metabolic Recovery in Discarded Human Livers Eight discarded extended-criteria donor human livers underwent 12 hours of OrganOx metra® NMP with NucleoCapture, followed by six hours of whole-blood reperfusion modeling ~84% Reduction in Circulating NETs 13.54
Slide 25: DNase Improves In Vivo Efficacy of CAR T Cells
DNase Improves In Vivo Efficacy of CAR T Cells Mice treated by CAR19 T cells in combination with DNase demonstrate improved survival and primary tumor clearance in leukemia and lymphoma models with improved CAR19 T cells expansion and persistence Enhanced CAR19 T cells Expansion and Persistence DNas
Slide 26: Investigator-Initiated Study in Large B-Cell Lymphoma
Investigator-Initiated Study in Large B-Cell Lymphoma Study Design Secondary Effectiveness Primary Effectiveness Endpoint Endpoint • ORR at 1 and 3 months after CART Number of Subjects Treatment CRR • PFS at 12 months post CAR T cells (complete response rate) • Duration of response (DOR) 12 subjects
Xenetic Biosciences — Merger or Acquisition (September 2026) on 6ix